Cholinesterase Inhibitors
- PMID: 31335056
- Bookshelf ID: NBK544336
Cholinesterase Inhibitors
Excerpt
Cholinesterase inhibitors function to decrease the breakdown of acetylcholine. They SEe use in the treatment of Alzheimer and dementia symptoms. This activity describes the indications, action, and contraindications for cholinesterase inhibitors in treating dementia disorders and other uses within other specialties. Moreover, this activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the management of patients undergoing treatments requiring cholinesterase inhibitors.
Copyright © 2025, StatPearls Publishing LLC.
Conflict of interest statement
Sections
Similar articles
-
Rivastigmine.2023 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32491370 Free Books & Documents.
-
Lurasidone.2023 Jun 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Jun 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31082101 Free Books & Documents.
-
Chloroquine.2023 Jul 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Jul 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31855356 Free Books & Documents.
-
Bleomycin.2023 Aug 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Aug 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32310355 Free Books & Documents.
-
A critical review of brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer's disease.Expert Rev Neurother. 2025 Jan;25(1):5-13. doi: 10.1080/14737175.2024.2407836. Epub 2024 Sep 29. Expert Rev Neurother. 2025. PMID: 39344050 Review.
References
-
- Ma SL, Tang NLS, Wat KHY, Tang JHY, Lau KH, Law CB, Chiu J, Tam CCW, Poon TK, Lin KL, Kng CPL, Kong HL, Chan TY, Chan WC, Lam LCW. Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease. Am J Alzheimers Dis Other Demen. 2019 Aug;34(5):302-307. - PMC - PubMed
-
- Lin YW, Truong D. Diffuse Lewy body disease. J Neurol Sci. 2019 Apr 15;399:144-150. - PubMed
-
- Masuda M, Utsumi H, Tanaka S, Maeno A, Yamamoto M, Sugiyama K, Hirano T, Aizawa H. Treatment of Myasthenia Gravis With High-Dose Cholinesterase Inhibitors and Calcineurin Inhibitors Caused Spontaneous Muscle Cramps in Patients. Clin Neuropharmacol. 2018 Sep/Oct;41(5):164-170. - PubMed
Publication types
LinkOut - more resources
Full Text Sources